Paul G Polakis

Title: Paul G Polakis: Innovator in Cancer Research

Introduction

Paul G Polakis is a prominent inventor based in San Francisco, CA. He has made significant contributions to the field of cancer research, particularly through his innovative patents. With a total of 2 patents, Polakis has focused on developing methods and compositions that target oncogenes and tumor suppressor genes.

Latest Patents

Polakis's latest patents include "Modulators of BRCA1 activity" and "GTPase activating protein fragments." The first patent describes compositions of matter consisting of nucleotide sequences that encode proteins known as BRCA1 Modulator Proteins. These proteins bind to the tumor suppressor gene product BRCA1 and are utilized in diagnosing and treating diseases associated with BRCA1. The second patent outlines peptides that inhibit the hydrolysis of GTP by GAP-stimulated ras p21, which are useful as cancer diagnostics and therapeutics. These peptides can detect cancer cells with an overexpression of normal or oncogenic ras p21 protein and provide methods for treating cancer caused by ras oncogenes.

Career Highlights

Throughout his career, Polakis has worked with notable companies such as Onyx Pharmaceuticals, Inc. and Chiron Corporation. His work in these organizations has contributed to advancements in cancer treatment and diagnostics.

Collaborations

Polakis has collaborated with esteemed colleagues, including Bonnee Rubinfeld and Terilyn T Vuong. These partnerships have further enhanced his research and innovation in the field.

Conclusion

Paul G Polakis is a distinguished inventor whose work has significantly impacted cancer research. His innovative patents and collaborations continue to pave the way for advancements in cancer diagnostics and therapeutics.